Recent Analysts’ Ratings Changes for Bruker (BRKR)

A number of firms have modified their ratings and price targets on shares of Bruker (NASDAQ: BRKR) recently:

• 11/6/2024 – Bruker had its price target lowered by analysts at Wells Fargo & Company from $78.00 to $75.00. They now have an “overweight” rating on the stock.
• 11/6/2024 – Bruker had its price target lowered by analysts at Barclays PLC from $75.00 to $69.00. They now have an “overweight” rating on the stock.
• 11/6/2024 – Bruker had its price target lowered by analysts at TD Cowen from $72.00 to $70.00. They now have a “hold” rating on the stock.
• 11/6/2024 – Bruker had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a “buy” rating on the stock.
• 10/15/2024 – Bruker is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $75.00 price target on the stock.
• 9/30/2024 – Bruker was downgraded by analysts at Wolfe Research from an “outperform” rating to a “peer perform” rating.

Bruker Stock Performance

Shares of BRKR traded down $2.76 during mid-day trading on Friday, reaching $57.73. The company had a trading volume of 1,076,633 shares, compared to its average volume of 1,072,925. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18. Bruker Co. has a 52-week low of $54.55 and a 52-week high of $94.86. The stock has a 50 day moving average of $63.83 and a two-hundred day moving average of $66.47. The stock has a market capitalization of $8.74 billion, a P/E ratio of 23.95, a PEG ratio of 2.32 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The business’s quarterly revenue was up 16.4% on a year-over-year basis. During the same period last year, the company posted $0.74 earnings per share. On average, analysts expect that Bruker Co. will post 2.61 earnings per share for the current year.

Institutional Trading of Bruker

Several large investors have recently bought and sold shares of BRKR. Marshall Wace LLP increased its stake in shares of Bruker by 127.8% in the 2nd quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock worth $88,666,000 after acquiring an additional 779,549 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Bruker in the 2nd quarter valued at approximately $36,472,000. AQR Capital Management LLC raised its position in shares of Bruker by 123.6% during the 2nd quarter. AQR Capital Management LLC now owns 555,468 shares of the medical research company’s stock valued at $35,444,000 after buying an additional 307,021 shares during the period. Vaughan Nelson Investment Management L.P. lifted its holdings in Bruker by 78.3% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 593,091 shares of the medical research company’s stock valued at $37,845,000 after acquiring an additional 260,363 shares during the last quarter. Finally, Point72 Europe London LLP increased its stake in Bruker by 262.9% during the second quarter. Point72 Europe London LLP now owns 333,997 shares of the medical research company’s stock worth $21,312,000 after acquiring an additional 241,959 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.